Theranib Revenue

Biotechnology Research • 1300-1969 Upper Water Street, McInnes Cooper Tower, Canada • 1-10 Employees

Theranib revenue & valuation

Annual revenue	$85,555
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$273,776
Total funding	No funding

Key Contact at Theranib

Paola Marcato

Co-President

Company overview

Headquarters	1300-1969 Upper Water Street, McInnes Cooper Tower, Halifax, Nova Scotia NS B3J 3R7, CA
Website	theranib.com
NAICS	541714
Founded	2023
Employees	1-10

About Theranib

At Theranib Inc., we are dedicated to revolutioning cancer treatment by addressing the most pressing challenges in oncology: chemotherapy resistance and metastasis. Through our groundbreaking research and development of ALDH1A3-targeted therapies, we aim to deliver life-changing solutions for patients worldwide. Founded by leading scientists from Dalhousie University in Nova Scotia, Canada, and the University of Pisa, Italy, Theranib combines world-class expertise in molecular cancer biology and medicinal chemistry. Our proprietary compound, CLM296, represents a first-in-class therapeutic innovation designed to enhance the effectiveness of cancer treatments and improve patient outcomes. Supported by key funding sources, including the Canadian Institutes of Health Research and Invest Nova Scotia, we are advancing our mission to set a new standard in precision medicine. With a strong commitment to innovation and collaboration, Theranib is paving the way for the future of cancer care.

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Vice President

Funding Data

Theranib has never raised funding before.

Frequently asked questions

Theranib is located in 1300-1969 Upper Water Street, McInnes Cooper Tower, CA.

Theranib generates an estimated annual revenue of $85,555. This revenue figure reflects the company's market position and business performance in its industry.

Theranib has an estimated valuation of $273,776. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Theranib was founded in 2023, making it 3 years old. The company has established itself as a significant player in its industry over this time.

Theranib has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at Theranib

Paola Marcato

Co-President

4.8

40,000 users